Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis;Fatores associados à adesão a diferentes esquemas de tratamento com antimoniato de meglumina em ensaio clínico para leishmaniose cutânea

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 56, Issue 4, 2014, Pages 291-296

  Ribeiro, Madelon Novato ^a   Pimentel, Maria Inês Fernandes Pimentel ^a   Schubach, Rmando De Oliveira ^a   de Oliveira, Raquel de Vasconcellos Carvalhães ^a   Teixeira, José Liporage ^a   Leite, Madson Pedro da Silva Leite ^a   Fonseca, Monique ^a   Santos, Ginelza Peres Lima dos Santos ^a   Salgueiro, Mariza Matos ^a   e Vasconcellos, Erica de Camargo Ferreira ^a   Lyra, Marcelo Rosandiski ^a   Saheki, Mauricio Naoto ^a   Valete Rosalino, Claudia Maria ^a,b  

^a Funda??o Oswaldo Cruz   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Adherence; Cutaneous leishmaniasis; Pentavalent antimonials; Therapy; Treatment

Indexed keywords

MEGLUMINE ANTIMONATE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; FEMALE; HEALTH CARE PERSONNEL; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MODIFIED MORISKY TEST; MONITORING CARD; MORISKY TEST; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; SOUNTING OF VIAL SURPLUS;

ADOLESCENT; ADULT; AGED; ANTIPROTOZOAL AGENTS; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PATIENT COMPLIANCE; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84905161086     PISSN: 00364665     EISSN: 16789946     Source Type: Journal    
DOI: 10.1590/S0036-46652014000400004     Document Type: Article

References (35)

1. Ashford RW. The leishmaniasis as emerging and reemerging zoonoses. Int J Parasitol. 2000;30:1269-81.
2. Azeredo-Coutinho RB, Mendonca SC. An intermittent schedule is better than continuous regimen of antimonial therapy for cutaneous leishmaniasis in the municipality of Rio de Janeiro, Brazil. Rev Soc Bras Med Trop. 2002;35:477-81.
3. Brazilian Central Bank. Currency conversion. [cited 2012 January 01]. Available from: http://www4.bcb.gov.br/pec/conversao/conversao.asp
4. Chulay JD, Fleckenstein L, Smith DH. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans R Soc Trop Med Hyg. 1988;82:69-72.
5. Conrad P. The meaning of medication: another look at compliance. Soc Sci Med. 1985;20:29-37.
6. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment techinique. JAMA. 1989;261:3273-7.
7. Goldberg AL, Cohen G, Rubin AH. Physician assessments of patient compliance with medical treatment. Soc Sci Med. 1998;47:1873-6.
8. Goodwin LG, Page JE. A study of the excretion of organic antimonials using a polarographic procedure. Biochem J. 1943;37:198-209.
9. Goodwin LG. Pentostam (sodium stibogluconate): a 50-year personal reminiscence. Trans R Soc Trop Med Hyg. 1995;89:339-41.
10. Herwaldt BL. Leishmaniasis. Lancet. 1999;354(9185):1191-9.
11. Haynes RB, Taylor DW, Sackett DL, editors. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979.
12. Landis JR, Kock GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74.
13. Leite SN, Vasconcellos MPC. Adesão à terapêutica medicamentosa: elementos para a discussão de conceitos e pressupostos adotados na literatura. Cienc Saúde Colet. 2003;8:775-82.
14. Lira KB, Leite JJG, Maia DCBSC, Freitas RMF, Feijão AR. Knowledge of the patients regarding leprosy and adherence to treatment. Braz J Infect Dis. 2012;16:472-5.
15. Maciel ELN, Silva AP, Meireles W, Fiorotti K, Hadad DJ, Dietze R. Tratamento supervisionado em pacientes portadores de tuberculose utilizando supervisores domiciliares em Vitória, Brasil. J Bras Pneumol. 2008;34:506-13.
16. Marinker M, Shaw J. Not to be taken as directed: putting concordance for taking medicines into practice. BMJ. 2003;326:348-9.
17. Miekeley N, Mortari SR, Schubach AO. Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis. Anal Bioanal Chem. 2002;372:495-502.
18. Ministerio da Saude. Secretaria de Vigilancia em Saude. Manual de vigilancia da Leishmaniose Tegumentar Americana. 2. ed. atual. Brasilia: Ministerio da Saúde; 2010.
19. Morisky DE, Levine DM, Green LW, Smith CR. Health education program effects on the management of hypertension in the elderly. Arch Int Med. 1982;142:1835-8.
20. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
21. Oliveira-Neto MP, Schubach A, Mattos M, Gonçalves-Costa SC, Pirmez C. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/ day) and high dosage (20 mg/kg/day) antimony regimens. Path Biol. 1997;45:496-9.
22. Oliveira-Neto MP, Schubach A, Mattos M, da Costa SC, Pirmez C. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil - an area of Leishmania (V.) braziliensis transmission. Int J Dermatol. 1997A;36:463-8.
23. Oliveira-Neto MP, Mattos M, Pirmez C, Fernandes O, Gonçalves-Costa SC, Souza CFS, et al. Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime ®) in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo. 2000;42:321-5.
24. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-97.
25. Passos VMA, Barreto SM, Romanha AJ, Krettli AU, Volpini AC, Gontijo CM, et al. Leishmaniose tegumentar na região metropolitana de Belo Horizonte: aspectos clínicos, laboratoriais, terapêuticos e evolutivos (1989-1995). Rev Soc Bras Med Trop. 2001;34:5-12.
26. Roberts WL, Berman JD, Rainey PM. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob Agents Chemother. 1995;39:1234-9.
27. Schubach AO, Marzochi KBF, Moreira JS, Schubach TM, Araujo ML, Vale AC, et al. Restrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate. Rev Soc Bras Med Trop. 2005;38:213-7.
28. Shaw JJ. Taxonomy of genus Leishmania: present and future trends and their implications. Mem Inst Oswaldo Cruz. 1994;89:471-8.
29. Valencia C, Arévalo J, Dujardin JC, Llanos-Cuentas A, Chappuis F, Zimic M. Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions. PLoS Negl Trop Dis. 2012;6:e1656. doi: 10.1371/journal. pntd.0001656. Epub 2012 Jun 12.
30. Vasconcellos EFC, Schubach AO, Valete-Rosalino CM, Coutinho RS, Conceição- Silva F, Salgueiro MM, et al. American tegumentary leishmaniasis in older adults: 44 cases treated with an intermittent low-dose antimonial schedule in Rio de Janeiro, Brazil. J Am Geriatr Soc. 2010;58:614-6.
31. Vasconcellos EC, Pimentel MIF, Schubach AO, de Oliveira RV, Azeredo-Coutinho RB, Silva FC, et al. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006). Am J Trop Med Hyg. 2012;87:257-60.
32. Váquez L, Scorza Dagert JV, Scorza JV, Vicuña-Fernández N, Petit de Peña Y, López S, et al. Pharmacokinetics of experimental pentavalent antimony after intramuscular administration in adult volunteers. Curr Ther Res Clin Exp. 2006;67:193-203.
33. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive rewiew. J Clin Pharm Ther. 2001;26:331-42.
34. World Health Organization. Letter to Aventis pharma drug regulatory affairs, Europe. Essential drugs and medicines policy. Geneva: WHO; 2001.
35. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO; 2003.